声明：市场有风险，投资需谨慎。本文为AI基于第三方数据生成，仅供参考，不构成个人投资建议。 来源：市场资讯 有投资者在互动平台向特宝生物提问："目前，中国医药海外BD如火如荼。请问派格宾有这样的可能 吗？" 针对上述提问，特宝生物回应称："您好！派格宾作为全球首个以乙肝临床治愈为治疗目标的药物，有 望助力更多乙肝患者实现更高的治疗目标，未来公司将根据经营情况进一步拓展国际业务。感谢您的关 注。" ...

经济观察网特宝生物近期公告显示，公司拟发行可转换公司债券募集资金总额不超过15.33亿元，用于 新药研发等项目。同时，公司2025年业绩快报显示营业收入36.96亿元，同比增长31.18%，归母净利润 10.38亿元，同比增长25.39%。 定增股票 业绩经营情况 公司于2026年2月10日晚间披露了2025年业绩快报，显示营业收入36.96亿元，同比增长31.18%，归母净 利润10.38亿元，同比增长25.39%。业绩增长主要受重点产品派格宾销售收入稳定增长及新产品益佩生 上市推动。 以上内容基于公开资料整理，不构成投资建议。 特宝生物于2026年1月26日晚间公告，拟发行可转换公司债券募集资金总额不超过15.33亿元，用于新药 研发项目、生物技术创新融合中心建设项目及创新药物生产改扩项目。这一计划旨在加码主业，提升研 发能力和产能。 ...

长效生物制剂龙头特宝生物(688278.SH)经营业绩再现稳健增长。 2月10日晚，特宝生物披露了2025年业绩快报。当年，公司实现的营业收入、归母净利润分别为36.96亿 元、10.38亿元，同比增速均超过20%，均创下历史新高。 特宝生物解释，公司重点产品销售收入稳定增长，新产品获批上市带来销售收入新增长点。 长江商报记者发现，2018年至2025年的八个年度，特宝生物的营收净利实现了连续八年增长。 与业绩增长相关联的是，特宝生物的经营现金流持续净流入。2025年前三季度，公司经营现金流净额为 4.71亿元，同比增长61.33%。 特宝生物重点聚焦乙肝临床治愈领域，截至2025年6月末，公司已经上市六个药品及一款电子笔式注射 器。 特宝生物的研发投入持续增加，2025年前三季度，公司研发投入为3.12亿元，同比增长38.67%。 特宝生物持续回报股东。2020年上市以来，公司已经连续五年分红，合计分红5.67亿元，为股权融资额 的1.5倍。 年度盈利首次突破10亿大关 特宝生物业绩延续双增的良好发展势头。 根据最新发布的业绩快报，2025年，特宝生物实现营业收入36.96亿元，同比增长31.18%；归母净 ...

Core Viewpoint - The company reported significant growth in both revenue and net profit for the year 2025, driven by stable sales of key products and the introduction of new products [1] Financial Performance - The company achieved an annual revenue of 3.696 billion yuan, representing a year-on-year increase of 31.18% [1] - The net profit attributable to shareholders reached 1.038 billion yuan, reflecting a year-on-year growth of 25.39% [1] Key Growth Drivers - The substantial revenue growth is primarily attributed to the stable sales of the key product, Paigebin [1] - The approval and market launch of the new product, Yipeisheng, provided a new revenue growth point for the company [1]

Core Viewpoint - The company, Xiamen Te Bao Biological Engineering Co., Ltd., reported steady growth in its 2025 annual performance, with significant increases in revenue and profit metrics, leading to a rise in stock price and market capitalization [1][7]. Financial Performance - Total operating revenue for 2025 reached 3.696 billion RMB, a year-on-year increase of 31.18% from 2.817 billion RMB [3][4]. - Operating profit was 1.254 billion RMB, up 29.14% from 971 million RMB in the previous year [3][4]. - Total profit amounted to 1.178 billion RMB, reflecting a 26.56% increase from 931 million RMB [3][4]. - Net profit attributable to shareholders was 1.038 billion RMB, a 25.39% rise from 828 million RMB [3][4]. - Basic earnings per share were 2.55 RMB, up 25.62% from 2.03 RMB [3][4]. Asset Status - Total assets at the end of the reporting period were 4.369 billion RMB, a 43.21% increase from 3.050 billion RMB at the beginning of the period [3][4]. - Shareholders' equity attributable to the parent company was 3.456 billion RMB, up 35.36% from 2.553 billion RMB [3][4]. - The net asset value per share attributable to the parent company was 8.47 RMB, a 34.87% increase from 6.28 RMB [3][4]. Growth Drivers - The growth in performance is attributed to the dual drivers of core products and new product launches, particularly the approval of Peginterferon α-2b injection for chronic hepatitis B and the new product Yipeisheng [5][13]. - Peginterferon has shown significant clinical efficacy, with a cure rate exceeding 30% and a maintenance rate of 90% over two years [5][13]. - Yipeisheng has been included in the national medical insurance directory, contributing to new revenue growth [5][13]. Market Outlook - Guojin Securities highlighted the company's leadership in PEG long-acting drugs, with three approved products, and expects accelerated growth in 2026 as new indications and insurance coverage take effect [6][15]. - The company is also expanding into innovative fields such as small nucleic acid drugs and antibody drugs, with plans to raise 1.533 billion RMB for new drug development [6][15]. - Profit forecasts for 2025-2027 predict net profits of 1.036 billion RMB, 1.402 billion RMB, and 1.769 billion RMB, representing growth rates of 25.2%, 35.3%, and 26.1% respectively [6][15].

Economic News - The People's Bank of China (PBOC) will continue to implement a moderately loose monetary policy, utilizing various policy tools such as reserve requirement ratio (RRR) cuts and interest rate reductions to maintain ample liquidity and relatively loose social financing conditions [1] - The National Bureau of Statistics released the Consumer Price Index (CPI) and Producer Price Index (PPI) data for January, indicating a month-on-month increase of 0.2% in CPI and a year-on-year increase of 0.2%, while core CPI (excluding food and energy) rose by 0.8% [2][4] - The logistics sector showed a total social logistics volume of 368.2 trillion yuan in 2025, with a year-on-year growth of 5.1%, indicating strong support for the real economy [5] Company Insights - Semiconductor Manufacturing International Corporation (SMIC) reported a revenue of 17.813 billion yuan for Q4 2025, a year-on-year increase of 11.9%, with a net profit of 1.223 billion yuan, up 23.2% [6][7] - Huaxia Fund, a subsidiary of CITIC Securities, achieved a revenue of 9.626 billion yuan and a net profit of 2.396 billion yuan in 2025, with total managed assets reaching 3.01 trillion yuan [7] - In 2025, Huizhou Technology expects a net profit of 4.971 billion to 5.399 billion yuan, representing a growth of 16% to 26% year-on-year, driven by good revenue growth and effective cost control [8] - Newhan New Materials plans to raise up to 1 billion yuan through a private placement to fund projects related to high-performance resins and composite materials [9] - Teabo Bio reported a total revenue of 3.696 billion yuan in 2025, a year-on-year increase of 31.18%, with a net profit of 1.038 billion yuan, up 25.39% [9] Industry Analysis - The global IC substrate market is projected to reach 16.69 billion USD in 2025 and grow to 18.44 billion USD in 2026, driven by the demand for AI and high-performance computing [12][13] - The demand for IC substrates is expected to continue rising due to the rapid growth in AI applications and high-performance computing, with a compound annual growth rate (CAGR) of 10.51% anticipated from 2026 to 2035 [13] - The company is positioned to benefit from the AI wave, with its PCB and semiconductor businesses expected to perform well, projecting earnings per share (EPS) of 0.08 yuan, 0.25 yuan, and 0.40 yuan for 2025 to 2027 [14]

（特宝生物公告） 报告期内，公司整体经营及财务状况稳健，主要得益于重点产品派格宾销售收入的稳定增长以及新产品 益佩生的上市带来的新销售增长点。尽管新产品上市初期市场拓展及核心产品覆盖提升导致相关费用增 加，但公司创新成果的快速临床应用推动了整体经营的稳健增长。 近日，特宝生物发布公告称，2025年度公司实现营业总收入36.96亿元，同比增长31.18%；归母净利润 为10.38亿元，同比增长25.39%。 ...

报告期内公司营业总收入实现较大增长，主要原因是重点产品派格宾销售收入稳定增长，新产品益佩生 获批上市带来销售收入新增长点。 智通财经APP讯，特宝生物(688278.SH)披露2025年度业绩快报，2025年度实现营业总收入36.96亿元， 同比增长31.18%;归属于母公司所有者的净利润10.38亿元，同比增长25.39%。 ...

特宝生物(688278.SH)披露2025年度业绩快报，2025年度实现营业总收入36.96亿元，同比增长31.18%;归 属于母公司所有者的净利润10.38亿元，同比增长25.39%。 报告期内公司营业总收入实现较大增长，主要原因是重点产品派格宾销售收入稳定增长，新产品益佩生 获批上市带来销售收入新增长点。 ...

（文章来源：北京商报） 特宝生物表示，报告期内，随着公司产品派格宾联合核苷（酸）类似物用于成人慢性乙型肝炎患者的 HBsAg持续清除增加适应症的获批，以及乙肝临床治愈相关科学证据的不断积累，派格宾作为全球首个 以乙肝临床治愈为治疗目标的药物，在慢乙肝临床治愈联合治疗中的基石地位进一步凸显；新产品益佩 生获批上市并纳入《国家基本医疗保险、工伤保险和生育保险药品目录》，凭借安全、有效、便捷的优 势，产品的市场推广工作进展顺利。尽管受新产品上市初期市场拓展、核心产品加大覆盖提升等因素影 响，相关费用有所增加，但公司全力推动创新成果快速进入临床应用，整体经营仍保持稳健增长。 北京商报讯2月10日晚间，特宝生物（688278）发布2025年度业绩快报显示，公司2025年营业收入36.96 亿元，同比增长31.18％；归属净利润10.38亿元，同比增长25.39％。 ...